Compare iShares MSCI Japan ETF (EWJ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Sanofi SA — how do they compare? iShares MSCI Japan ETF trades at $97.86 (market cap $23.87B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 4× iShares MSCI Japan ETF's market cap, and Sanofi SA pays a 6.01% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Sanofi SA for 94 Days on average.
| EWJ | SNY | |
|---|---|---|
Market Cap | $23.87B | $95.18B |
Volume | 5,412,820 | 2,995,646 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $52.34 |
52-Week Low | $78.36 | $39.51 |
Typical Hold Time | 56 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.32, down 1.02% on the day. Technical indicators show a neutral overall signal with mixed moving averages and oscillators. Recent news highlights Japan's monetary policy uncertainty as the Bank of Japan navigates rate hikes amid fiscal stimulus concerns. The ETF remains positioned within a tight trading range between $96 support and $99 resistance levels.
Outlook remains cautious as Japan faces monetary tightening headwinds while maintaining fiscal stimulus. Investment opportunity exists in Japan's AI and semiconductor exposure, though currency volatility and rising bond yields present near-term risks. The neutral technical stance suggests limited directional momentum pending clearer policy signals from Japanese authorities.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
